Advertisement
DVAX vs INCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and INCR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DVAX’s FA Score shows that 0 FA rating(s) are green whileINCR’s FA Score has 1 green FA rating(s).
- DVAX’s FA Score: 0 green, 5 red.
- INCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DVAX’s TA Score shows that 5 TA indicator(s) are bullish while INCR’s TA Score has 5 bullish TA indicator(s).
- DVAX’s TA Score: 5 bullish, 4 bearish.
- INCR’s TA Score: 5 bullish, 5 bearish.
Price Growth
DVAX (@Pharmaceuticals: Generic) experienced а +4.45% price change this week, while INCR (@Pharmaceuticals: Generic) price change was +8.67% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.
Reported Earning Dates
DVAX is expected to report earnings on Oct 30, 2025.
INCR is expected to report earnings on Aug 18, 2025.
Industries' Descriptions
@Pharmaceuticals: Generic (+4.25% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| DVAX | INCR | DVAX / INCR | |
| Capitalization | 1.27B | 88.9M | 1,423% |
| EBITDA | -40.59M | -39.54M | 103% |
| Gain YTD | -15.505 | 2.516 | -616% |
| P/E Ratio | 54.60 | 25.48 | 214% |
| Revenue | 295M | 273M | 108% |
| Total Cash | 661M | 20.3M | 3,256% |
| Total Debt | 286M | 151M | 189% |
DVAX | INCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 94 | 100 | |
SMR RATING 1..100 | 93 | 94 | |
PRICE GROWTH RATING 1..100 | 57 | 52 | |
P/E GROWTH RATING 1..100 | 97 | 5 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCR's Valuation (61) in the Servicestothe Health Industry industry is in the same range as DVAX (72) in the Biotechnology industry. This means that INCR’s stock grew similarly to DVAX’s over the last 12 months.
DVAX's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.
DVAX's SMR Rating (93) in the Biotechnology industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.
INCR's Price Growth Rating (52) in the Servicestothe Health Industry industry is in the same range as DVAX (57) in the Biotechnology industry. This means that INCR’s stock grew similarly to DVAX’s over the last 12 months.
INCR's P/E Growth Rating (5) in the Servicestothe Health Industry industry is significantly better than the same rating for DVAX (97) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than DVAX’s over the last 12 months.
| DVAX | INCR | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 73% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 74% | 3 days ago 75% |
| MACD ODDS (%) | 3 days ago 78% | 3 days ago 77% |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 77% |
| TrendMonth ODDS (%) | 3 days ago 74% | 3 days ago 72% |
| Advances ODDS (%) | 5 days ago 75% | 6 days ago 73% |
| Declines ODDS (%) | 10 days ago 78% | 19 days ago 80% |
| BollingerBands ODDS (%) | 3 days ago 68% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 77% | 3 days ago 75% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VGQRX | 17.56 | 0.08 | +0.46% |
| Virtus KAR Global Quality Dividend R6 | |||
| HDVAX | 14.66 | 0.06 | +0.41% |
| Hartford International Equity A | |||
| WEUSX | 14.56 | 0.03 | +0.21% |
| SEI World Equity Ex-US A (SIIT) | |||
| MADSX | 28.77 | N/A | N/A |
| Morgan Stanley Inst Advantage R6 | |||
| JMVCX | 15.69 | -0.11 | -0.70% |
| Janus Henderson Mid Cap Value C | |||
DVAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.
| Ticker / NAME | Correlation To DVAX | 1D Price Change % | ||
|---|---|---|---|---|
| DVAX | 100% | +1.60% | ||
| ACET - DVAX | 39% Loosely correlated | +0.80% | ||
| SNDL - DVAX | 35% Loosely correlated | -4.27% | ||
| ALKS - DVAX | 34% Loosely correlated | +2.80% | ||
| BCRX - DVAX | 33% Poorly correlated | -0.95% | ||
| ESPR - DVAX | 32% Poorly correlated | -0.97% | ||
More | ||||
INCR and
Correlation & Price change
A.I.dvisor tells us that INCR and SNDL have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and SNDL's prices will move in lockstep.
| Ticker / NAME | Correlation To INCR | 1D Price Change % | ||
|---|---|---|---|---|
| INCR | 100% | -1.81% | ||
| SNDL - INCR | 25% Poorly correlated | -4.27% | ||
| ACB - INCR | 24% Poorly correlated | -5.75% | ||
| OGI - INCR | 24% Poorly correlated | -8.33% | ||
| DVAX - INCR | 23% Poorly correlated | +1.60% | ||
| SUPN - INCR | 23% Poorly correlated | +1.23% | ||
More | ||||